Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal

Am J Obstet Gynecol. 1992 Oct;167(4 Pt 1):942-5. doi: 10.1016/s0002-9378(12)80016-0.

Abstract

Objectives: Our objectives were to assess erythrocyte aggregation in hypertensive pregnancy and to evaluate the effect of the antihypertensive treatment on it.

Study design: The mean entity of erythrocyte aggregation was determined by an automatic aggregometer in 57 pregnant women: 20 normotensive, seven chronically hypertensive, 10 chronically hypertensive with superimposed preeclampsia, and 20 with preeclampsia. Ten of the latter were subsequently treated by 40 mg/day oral nifedipine; the other 10 by 400 mg/day oral labetalol, to keep diastolic blood pressure < 90 mm Hg. Also, patients with superimposed preeclampsia were treated with 40 mg/day oral nifedipine.

Results: Erythrocyte aggregation was increased in all the hypertensive pregnant patients compared with the normotensive pregnant controls, regardless of both the onset (chronic or pregnancy-induced) of hypertension and the status of plasma macromolecules. Antihypertensive treatment with labetalol significantly reduced the aggregability of erythrocytes, whereas treatment with nifedipine reverted it to normal.

Conclusions: Increased erythrocyte aggregation may be due to either conformational changes of the membrane occurring during hypertension or a redistribution of the ionic charges on the two surfaces of the membrane. The effect of nifedipine by restoring the ionic charges may be due to this latter event.

MeSH terms

  • Erythrocyte Aggregation / drug effects*
  • Female
  • Humans
  • Nifedipine / therapeutic use*
  • Pre-Eclampsia / blood
  • Pre-Eclampsia / drug therapy*
  • Pregnancy
  • Reference Values

Substances

  • Nifedipine